Transfusion最新文献

{"title":"SARS-CoV-2 convalescent plasma for the controlled clinical trial \"COVIC-19\": Experience from collection of very high-titer plasma from superimmunized individuals.","authors":"Simone Hoffmann, Alina Seidel, Carolin Ludwig, Christiane Vieweg, Rebecca Müller, Henrike Hofmann, Bernd Jahrsdörfer, Patrick Wuchter, Harald Klüter, Michael Schmidt, Matthias Johnsen, Thomas Burkhardt, Thomas Appl, Eva Schrezenmeier, Jan Münch, Pierre Tiberghien, Hubert Schrezenmeier, Sixten Körper","doi":"10.1111/trf.18394","DOIUrl":"https://doi.org/10.1111/trf.18394","url":null,"abstract":"<p><strong>Background: </strong>COVID-19 convalescent plasma (CCP) is a treatment option for COVID-19. Understanding of donor and product characteristics is important for optimization of CCP therapy. We report the experience of collection of very high-titer CCP for the trial \"A randomized open-label trial of early, very high-titer convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19\" (COVIC-19) (NCT05271929).</p><p><strong>Study design and methods: </strong>Individuals who had recovered from COVID-19 and had ≥1 dose of a SARS-CoV-2 vaccine were recruited as donors for CCP. Anti-SARS-CoV-2 antibodies were measured by ELISA, and neutralization capacity against SARS-CoV-2 variants was assessed in surrogate and pseudovirus-neutralization assays. Correlation of antibody titers with donor characteristics and antibody kinetics was analyzed.</p><p><strong>Results: </strong>We recruited 688 potential donors. 41.4% of individuals had antibody concentrations of ≥4000 BAU/ml (anti-SARS-CoV-2 IgG ELISA [QuantiVac]). Concentrations did not significantly differ by sex or ABO type, but were higher among those who had received at least three vaccinations. Highest titers were observed in those with a breakthrough infection after two vaccinations, followed by a booster (median 5374 BAU/mL) or breakthrough infection after the 3rd or 4th vaccination (median 3846 BAU/mL). Ultimately, 172 eligible individuals donated CCP with a median concentration of 6858 BAU/mL (range 4015-22,923 BAU/mL).</p><p><strong>Discussion: </strong>We demonstrate the feasibility of the collection of very high-titer CCP products under a harmonized protocol for a randomized clinical trial, but it requires substantial donor selection, appropriate antibody assays, rapid succession of screening, and apheresis to take advantage of the short period of very high antibody concentrations.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145041332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunologic investigation of an allergic transfusion reaction suspected due to alpha-gal syndrome.","authors":"Victoria M Jones, Hirotomo Nakahara, Shailesh K Choudhary, Nancy M Dunbar, Zbigniew M Szczepiorkowski, Nora R Ratcliffe, Mark Cervinski, Andrew J Yanik, Mitchell Fuller, Brian C Spence, An V Huynh, Sean R Stowell, Scott P Commins, Richard M Kaufman","doi":"10.1111/trf.18405","DOIUrl":"https://doi.org/10.1111/trf.18405","url":null,"abstract":"<p><strong>Background: </strong>The bites of certain tick species can induce galactose-α-1,3-galactose (alpha-gal) IgE formation. Individuals with alpha-gal IgE can become allergic to meat, a condition termed alpha-gal syndrome. Alpha-gal is structurally related to B antigen. Recent case reports (Gilstad et al., 2023 and Miller et al., 2024) suggest that transfusing group B plasma or platelets to group O individuals with alpha-gal IgE can trigger severe allergic transfusion reactions. However, mechanistic evidence is lacking.</p><p><strong>Study design and methods: </strong>A 76-year-old group O man undergoing heart surgery became profoundly hypotensive after receiving 50 mL of a group B platelet unit. He recovered with diphenhydramine treatment. We investigated potential causes of anaphylaxis (alpha-gal syndrome; IgA deficiency; protamine, and rocuronium allergies). The platelet unit and patient samples were analyzed by flow cytometry. Indirect basophil activation tests (iBATs) were performed on the patient's plasma.</p><p><strong>Results: </strong>The patient's serum tryptase level spiked, consistent with anaphylaxis. His serum tested positive for alpha-gal IgE (1.49 kU/L). Flow cytometric analyses demonstrated that: (1) the transfused platelets expressed substantial B antigen, and (2) the patient's plasma contained IgE-recognizing alpha-gal and B antigen > A antigen. In iBATs, resting allogeneic basophils incubated with the patient's plasma showed equivalent (albeit weak) activation when stimulated with either alpha-gal or B antigen.</p><p><strong>Discussion: </strong>We report a case of anaphylactic shock in an O patient transfused with a B platelet unit. The in vitro data suggest, but do not prove, that the reaction was mediated by recipient alpha-gal IgE. Further studies are needed to establish whether transfusion-related alpha-gal syndrome (\"TRAGS\") is a true clinical entity.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145041406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of a novel B allele with a c.140_143del on the ABO*B.01 allele.","authors":"Shuang Liang, Fan Wu, Tong Liu, Li-Yan Sun, Hao Zhang","doi":"10.1111/trf.18404","DOIUrl":"https://doi.org/10.1111/trf.18404","url":null,"abstract":"","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145024313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nondisclosure of use of antiretroviral medications in Canadian blood donors.","authors":"Mindy Goldman, Steven J Drews, Chanson Brumme, Hope R Lapointe, Timothy Tang, Lori Osmond, Sheila F O'Brien","doi":"10.1111/trf.18393","DOIUrl":"https://doi.org/10.1111/trf.18393","url":null,"abstract":"<p><strong>Introduction: </strong>Donors are deferred if they are on antiretroviral medications (ARV) as post-exposure or pre-exposure prophylaxis (PEP or PrEP) for human immunodeficiency virus (HIV). We assessed donor compliance by measuring ARV levels in selected anonymized donor samples collected from September 22, 2022 to December 31, 2024, almost all after the introduction of sexual risk behavior screening.</p><p><strong>Methods: </strong>EDTA plasma samples collected at the time of donation (retention samples) were retrieved, frozen, and shipped for measurement of tenofovir and emtricitabine. Samples were from randomly selected first-time male donors in large urban areas (n = 520), syphilis (n = 133), or HIV (n = 6) confirmed positive donors, and donors deferred for PEP or PrEP use on a previous donation attempt who returned to successfully donate (n = 225 tests, 115 unique donors). We compare our results to international studies.</p><p><strong>Results: </strong>All samples from first-time male donors, HIV-positive donors, syphilis-positive female donors, and female donors previously deferred for PEP or PrEP were negative. Three of 110 male syphilis-positive donors (2.7%) and 14 of 85 male donors previously deferred for PEP or PrEP (16.5%) were positive for ARV. Eleven of these donors were tested multiple times, and 10 were positive more than once.</p><p><strong>Conclusion: </strong>Results on syphilis-positive male donors were similar to findings in England and the Netherlands. Noncompliance with criteria for ARV use was high in male donors previously deferred for PEP/PrEP. Messaging regarding recipient risk is particularly difficult in this group, since it is at odds with the reduction in individual HIV risk.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145016245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and window period residual risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus in United States blood donations, 2017 to 2023: The transfusion-transmissible infections monitoring system.","authors":"Emilya Huseynova, James Haynes, Edward P Notari, Brian Custer, Rita Reik, Jed Gorlin, Artur Belov, Benyam Hailu, Barbee Whitaker, Roger Y Dodd, Susan L Stramer","doi":"10.1111/trf.18398","DOIUrl":"https://doi.org/10.1111/trf.18398","url":null,"abstract":"<p><strong>Background: </strong>The Transfusion-Transmissible Infections Monitoring System assesses trends in ~60% of the US blood supply. Donors with high-risk behaviors, including injection drug use, men having sex with other men, or exchanging sex for money/drugs were deferred for 12 months (12M) from 2016 to 2020 and 3 months (3M) from 2020 to 2023. Here we evaluate HIV, HBV, and HCV incidence and window-period residual risk (WPRR) in two ~3-year periods of 12M (2017-2020) and 3M (2020-2023) to identify any differences.</p><p><strong>Methods: </strong>First-time (FT), repeat (RPT), and overall weighted incidence/100,000 person-years (phtpy) for HIV, HBV, and HCV were estimated based on serology and nucleic acid test results. WPRR was calculated by multiplying respective incidence by agent-specific WP. Fisher's exact test evaluated incidence changes between the two periods (α = 0.05).</p><p><strong>Results: </strong>Overall weighted incidence for HIV, HBV, and HCV was 2.22, 1.59, and 0.53 phtpy versus 1.03, 0.93, and 0.16 phtpy in 12M and 3M periods, respectively. Overall WPRR per 1,000,000 donations for HIV, HBV, and HCV was 0.45, 0.63, and 0.53 versus 0.23, 0.43, and 0.16 in 12M and 3M periods, respectively. All comparisons by agent and by period were significant (p < .01).</p><p><strong>Conclusions: </strong>Despite reducing donor deferral periods for many infectious risk behaviors, HIV, HBV, and HCV overall incidence declined from the 12M to 3M periods. WPRR also declined from 12M to 3M, remaining under 1 per 2,000,000 donations in the 3M period. Thus, changes in policy did not adversely impact the safety of the blood supply with respect to the major infectious disease agents.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145016275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma transfusion practice: A five-year audit of plasma transfusion at 23 hospitals.","authors":"Nadia Gabarin, Phuong Uyen Nguyen, Na Li, Anne Loeffler, Sheharyar Raza, Nicole Relke, Sarah Ryan, Justyna Bartoszko, Yang Liu, Malcolm Risk, Fahad Razak, Amol Verma, Donald M Arnold, Jeannie Callum","doi":"10.1111/trf.18400","DOIUrl":"https://doi.org/10.1111/trf.18400","url":null,"abstract":"<p><strong>Background: </strong>There is limited high-quality evidence to guide plasma transfusion, and plasma transfusion practices remain variable.</p><p><strong>Study design and methods: </strong>This is a retrospective cohort study that included adult medical and intensive care unit (ICU) inpatients (age ≥ 18 years) admitted to 23 hospitals in Canada between January 1, 2017, and December 31, 2022, when both whole blood derived (~290 mL) and apheresis plasma (~250 mL) were available for transfusion. Nine additional hospital sites with missing plasma data or coagulation testing were excluded. Data collected included patient demographics, most responsible diagnoses, procedures, laboratory tests, transfusion information, and physician characteristics.</p><p><strong>Results: </strong>Among 950,740 included hospital admissions at 23 hospitals, there were 11,163 admissions with plasma use, with 46,377 plasma units transfused. Of the plasma recipients, 63.5% were male, with a mean age of 61.2 years (SD 16.4). Most plasma transfusions were administered in the ICU (64.1%). The number of plasma units transfused per 1000 inpatient days across centers varied from a median (IQR) of 0.2 (0.1-0.4) to 11.0 (10.6-12.0) units. There was significant variability in pre-transfusion INR values across hospitals (ranging from a median (IQR) of 1.5 (1.3-1.9) to 2.5 (1.4-4.6)) and physician specialties (ranging from a median (IQR) of 1.4 (1.3-1.8) to 2.2 (1.8-3.0)). There was no significant change in plasma utilization over the study period.</p><p><strong>Discussion: </strong>This study demonstrated variability in plasma utilization and pre-transfusion INR thresholds across hospitals and physician specialties. This highlights the importance of developing evidence-based guidelines and effective knowledge translation to guide appropriate plasma use.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of blood group variants in an Omani population by comparison of whole genome sequencing and serology.","authors":"Paige E Haffener, Arwa Z Al-Riyami, Shoaib Al-Zadjali, Mohammed Al-Rawahi, Saif Al Hosni, Ali Al Marhoobi, Ammar Al Sheriyani, Ellen M Leffler","doi":"10.1111/trf.18401","DOIUrl":"10.1111/trf.18401","url":null,"abstract":"<p><strong>Background: </strong>Although blood group variation was first described over a century ago, our understanding of the genetic variation affecting antigenic expression on the red blood cell surface in many populations is lacking. This deficit limits the ability to accurately type patients, especially as serological testing is not available for all described blood groups, and targeted genotyping panels may lack rare or population-specific variants.</p><p><strong>Study design and methods: </strong>Here, we perform serological assays across 24 antigens and whole genome sequencing on 100 Omanis, a population underrepresented in genomic databases. We inferred blood group phenotypes using known genetic variants underlying antigen expression.</p><p><strong>Results: </strong>Comparison of serological to genetically inferred phenotypes resulted in an average prediction accuracy of 98.7%. By investigating 12 discordances, we describe candidate variants in the Lewis, Lutheran, MNS, and P1 blood groups that could affect antigenic expression, although further functional confirmation is required. We identify blood group alleles that, to our knowledge, have not been previously reported in Omanis, including several most common in African populations, likely introduced to Oman by gene flow over the last thousand years.</p><p><strong>Discussion: </strong>These findings highlight the need to evaluate individual populations and their population history when considering variants to include in genotype panels for blood group typing. This research will inform future genetic work in blood banks and transfusion services, ensuring that testing strategies are optimized for diverse genetic backgrounds.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145016303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preparation of cold-stored platelets on-demand: A novel approach to inventory management.","authors":"Lacey Johnson, Lauren Waters, Christopher Roan, Pearl Lei, Janhavi Mahajan, Mailys Portier, Ben Winskel-Wood, Denese C Marks","doi":"10.1111/trf.18396","DOIUrl":"https://doi.org/10.1111/trf.18396","url":null,"abstract":"<p><strong>Background: </strong>Cold-stored platelets (CSP) are now being used to treat acute bleeding. However, as CSP are less suitable for prophylaxis, both room temperature (RT) platelets and CSP will be required, which complicates inventory management. The production of CSP \"on-demand\" from RT platelets may be a desirable option. This study investigated whether CSP could be prepared rapidly by cooling RT platelets in a fridge or freezer.</p><p><strong>Study design and methods: </strong>Double apheresis platelet components (40% plasma/60% PAS-E) were sampled on Day 1 (RT baseline), then split into matched pairs (n = 10). One component was allocated to cold (2-6°C) storage and sampled at 2 h and 14 days. The other component was placed in a freezer (-30°C) and sampled every 5 min for 20 min (on-demand), then transferred to the fridge and sampled at 14 days.</p><p><strong>Results: </strong>Storage in the fridge for 2 h reduced the temperature to 4.1 ± 0.7°C and induced loss of swirl, shape change, enhanced aggregation, and reduced clotting time. Changes to surface glycoproteins (CD61, CD42b, GPVI) and activation markers (phosphatidylserine, P-selectin, release of alpha-granule proteins, and extracellular vesicles) were not observed after 2 h but became evident after 14 days. Storage in the freezer for at least 15 min induced the expected \"cold storage lesion\" changes.</p><p><strong>Discussion: </strong>The morphological and functional characteristics of CSP can be induced within 15 min by exposure to a standard blood-bank freezer, or 2 h in the fridge. This approach to prepare CSP \"on-demand\" may represent a viable option for balancing patient-tailored transfusion and inventory management.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145001168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How do I implement a whole blood program with low blood wastage?","authors":"Denise Bäckström, Malin Jonsson Fagerlund, Stella Larsson, Aseel Alshamari, Ragnar Henningsson, Karin Holst, Anna-Maria Harstad, Norbert Lubenow, José-Gabriel Sato Folatre, Pia Remneberg Carlbom, Agneta Wikman","doi":"10.1111/trf.18402","DOIUrl":"https://doi.org/10.1111/trf.18402","url":null,"abstract":"<p><strong>Background: </strong>The use of low-titer O whole blood (LTOWB) is requested in the treatment of major bleeding, initially used in military medicine but now increasingly utilized in civilian prehospital care. The advantage is the administration of a balanced transfusion, red blood cells, coagulation factors, and platelets, in one bag. The challenges are the availability of LTOWB and difficulties in predicting the need in major bleeding, leading to the risk of wastage.</p><p><strong>Methods: </strong>This study describes different logistical strategies when implementing whole blood in the Swedish civilian healthcare. The five transfusion centers producing whole blood in Sweden participated, providing experience of the production line, usage, and wastage.</p><p><strong>Results: </strong>In Sweden, LTOWB is used prehospital in helicopter emergency medical service (HEMS), in one physician-manned rapid response vehicle, and inhospital in three University Hospitals. The logistical strategies to reduce wastage vary but involve the rotation of LTOWB not used prehospital to inhospital use in two centers and the preparation of red blood cell (RBC) units from 1 to 2 weeks old LTOWB in three centers. The number of transfused LTOWB units varies between the centers, and wastage was 0%-13% in 4/5 centers and higher in one center, 34%.</p><p><strong>Conclusion: </strong>It is difficult to predict the need of LTOWB, requested in prehospital emergencies. Aiming for low wastage requires different logistical chains, depending on the local prerequisites. In Sweden, LTOWB is either rotated for use in major bleeding in hospital or prepared to RBC units after 1 week prehospital.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145001136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel RHD*01N allele harboring a c.634+1G>A splice site variant results in the RhD-negative phenotype in a Chinese blood donor.","authors":"Xu Zhang, Zhu-Ren Zhou, Xu-Ying Huang, Li-Chun Li, Xiao-Feng Li, Jian-Ping Li","doi":"10.1111/trf.18390","DOIUrl":"https://doi.org/10.1111/trf.18390","url":null,"abstract":"<p><strong>Background: </strong>The D-negative phenotype demonstrates significant ethnic diversity in its molecular background. This study reports the identification of a novel RHD*01 N allele resulting from a splicing site variation observed in a Chinese blood donor.</p><p><strong>Study design and methods: </strong>The D blood group phenotype was determined using serological techniques, including the saline method, and the indirect antiglobulin test (IAT) performed by both tube and microcolumn gel methods. Screening for the RHD gene was performed by directly amplifying exon 10 of the RHD gene from whole blood samples. Upon confirming the presence of the RHD gene in the sample, further detailed analysis was performed using Sanger sequencing and third-generation single-molecule real-time (SMRT) sequencing technologies. Additionally, the deep learning-based tool SpliceAI (Illumina, USA) was used to evaluate the potential impact of an unreported variant on splicing.</p><p><strong>Results: </strong>The D antigen in the proband's blood sample was detected as negative by both automated and manual methods. Exon 10 of the RHD gene was detected as positive. Sanger sequencing and third-generation single-molecule real-time (SMRT) sequencing were utilized for the detection of the RHD gene, and the results demonstrated that the sample carried a single RHD haplotype harboring a c.634+1G>A splice site variant. The SpliceAI prediction indicates that the c.634+1G>A splice site variant has a significant impact on splicing.</p><p><strong>Conclusion: </strong>A novel RHD allele harboring the c.634+1G>A splice site variant, which results in the RhD-negative phenotype, was identified and characterized in a Chinese blood donor.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145001089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}